One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Vyome Holdings, Inc.
HIND · NCM · Healthcare · Biotechnology
Current price
$1.87
52-week range
$1.75 - $6.56
Market cap
$13.12M
Balance sheet
Healthy
-18.73x Concerning
Net cash $7.87M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
2 Risks
0 rewards · 2 risks
- Risk Operating margin compressed from -288.4% to -3200.0% over 3 years.
- Risk Return on equity was -999.2% last year — the company lost money on shareholders' equity.
What this company does
Vyome Holdings, Inc.
Vyome Holdings, Inc. is a company developing new medicines for eye infections and skin conditions, primarily funded by its research and development activities. Their main goal is to create new treatments using their special molecular replacement therapy (MRT) platform, aiming to eventually sell these medicines to patients. This focus on innovation means their success hinges on getting their experimental drugs approved by regulators and finding partners to help bring them to market.
How the company got here
Vyome Holdings, Inc. (HIND) was formed in August 2025 through a merger between Vyome Therapeutics, Inc. and ReShape Lifesciences, Inc. [4, 5]. This transaction transformed Vyome Therapeutics, a clinical-stage biopharmaceutical company focused on developing treatments for immuno-inflammatory and rare diseases, into a publicly traded entity on the Nasdaq stock exchange [2, 4, 6]. The merger provided Vyome with access to public capital markets to fund its research and development pipeline and established a debt-free capital structure [4]. The company's origins trace back to 2008 when Vyome Therapeutics was founded with a focus on leveraging scientific understanding of disease mechanisms to create novel therapeutics [2, 3].
What it actually does
Vyome Holdings, Inc. is a specialty pharmaceutical company that develops therapeutic products targeting immuno-inflammatory and rare diseases [1, 3]. The company's approach involves identifying unmet medical needs and creating innovative treatments, often by leveraging a deep understanding of how diseases work [4, 7]. Vyome operates with a business model that bridges the U.S. and India, utilizing research and development in India for cost-efficiency while targeting high-margin markets in the U.S. [1, 8]. Their work involves advancing drug candidates through clinical trials, with the ultimate goal of commercialization and out-licensing [4].
Pharmaceutical products
Vyome's pharmaceutical segment includes legacy antifungal products and related commercial operations [1]. The company has successfully commercialized two reformulated topical antifungal products for dandruff in India, which are distributed through licensing and marketing agreements with Sun Pharma [6]. Additionally, they have an agreement with Sun Pharma for the development and licensing of an antifungal cream for skin fungal diseases specifically for the Indian market [6]. This segment represents the company's established commercial presence, distinct from its pipeline of new drug candidates [1].
Biotechnology pipeline
The core of Vyome's current focus is its biotechnology pipeline, which consists of clinical and preclinical drug candidates aimed at treating immune-inflammatory and rare diseases [1]. A key product candidate is VT-1953, a topical gel in Phase 2 clinical trials for conditions like bacterial conjunctivitis and malignant fungating wounds [1, 5, 8]. Another candidate, VT-1908, is a topical eye drop designed to treat inflammatory eye conditions without the side effects associated with steroids [2, 7]. The company is also developing VB-1953, a topical treatment for inflammatory acne that has completed Phase 2 clinical trials and is ready for Phase 3 [1, 3, 5]. This segment represents the company's future growth potential, driven by the development of novel therapies [1].
What management is betting on now
Vyome's management is strategically focused on advancing its clinical-stage assets, particularly those targeting immuno-inflammatory conditions [1, 9]. A primary priority is the development of VT-1953, which has shown promising results and is valued at approximately $1 billion by an independent firm after successful pivotal study data [9]. The company is also prioritizing VT-1908 and VB-1953, aiming to bring these novel therapies closer to market [11]. Vyome is leveraging its unique position across the U.S.-India innovation corridor, combining scientific expertise with capital efficiency to accelerate drug development and deliver value to both patients and shareholders [4, 9]. They are also exploring strategic alternatives for their stake in Livechain Inc., a company they hold a controlling interest in [10].
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
Revenue
$26.95K
Net income
$-685.56K
Diluted EPS
-0.10
Operating cash flow
$-903.71K
Free cash flow
—
Fetching…
Sources
Revenue
$31.59K
Net income
$-962.91K
Diluted EPS
-0.15
Operating cash flow
$-1.44M
Free cash flow
—
Fetching…
Sources
Revenue
$36.55K
Net income
$-672.20K
Diluted EPS
-18.47
Operating cash flow
$-1.48M
Free cash flow
—
Fetching…
Sources
Revenue
$34.63K
Net income
$-8.43M
Diluted EPS
-3.12
Operating cash flow
$4.34M
Free cash flow
—
Fetching…
Sources
Revenue
$1.24M
Net income
$-2.63M
Diluted EPS
-2.25
Operating cash flow
$-4.49M
Free cash flow
—
Fetching…
Sources
Revenue
$1.11M
Net income
$1.47M
Diluted EPS
18.98
Operating cash flow
$-2.12M
Free cash flow
—
Fetching…
Sources
Revenue
$1.80M
Net income
$-1.76M
Diluted EPS
-10.57
Operating cash flow
$-687.00K
Free cash flow
—
Fetching…
Sources
Revenue
$2.29M
Net income
$-1.58M
Diluted EPS
-3.11
Operating cash flow
$-311.00K
Free cash flow
—
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $1.87
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $7.9M - more cash than debt. Interest coverage -18.7x.
Net debt
$-7.87M
Interest coverage
-18.73x
Vyome Holdings, Inc. is healthier than 0 of 1 peers on balance-sheet leverage.
Healthy
Worse cushion
Baseline
Better cushion
HIND
BASELINE
Vyome Holdings, Inc.
Total debt $17.31K Interest coverage -18.73x This is the baseline the peer rows are being compared against.
What you should know
The case for and against HIND
0 Rewards
2 Risks
Rewards
Risks
-
Operating margin compressed from -288.4% to -3200.0% over 3 years.
-
Return on equity was -999.2% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
1.05x
Forward P/E
—
P/B
2.17x
P/S
101.17x
EV/EBITDA
-1.55x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
52.7%
Operating margin
-3,200.0%
Net margin
0.0%
ROE
-999.2%
ROA
-48.8%
Health
Liquidity and balance-sheet strength
Debt / equity
0.00x
Current ratio
4.37x
Quick ratio
4.31x
Total debt
$17.31K
Total cash
$7.89M
Growth
How the business has been compounding
Revenue TTM
$129.72K
Revenue 5Y CAGR
-60.8%
EPS TTM
1.78
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$524.47K
Free CF TTM
$-4.47M
FCF margin
-3,445.8%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—